{
  "disease_name": "Batten disease",
  "disease_id": "batten_disease",
  "pathogen_type": "genetic",
  "pathogen": "CLN gene deficiency (neuronal ceroid lipofuscinosis)",
  "target_classes": [
    "CLN_enzyme_replacement",
    "lysosomal_storage_clearance",
    "neuroprotective_agent"
  ],
  "primary_endpoints": [
    "neurological_decline_rate_reduction",
    "seizure_frequency_reduction",
    "motor_function_preservation",
    "CLN_enzyme_activity_restoration"
  ],
  "efficacy_threshold": 0.35,
  "ic50_max_um": 1.0,
  "ic50_optimal_um": 0.1,
  "selectivity_index_min": 50.0,
  "cc50_min_um": 100.0,
  "toxicity_threshold": 0.015,
  "molecular_weight_max": 600.0,
  "logp_min": -2.0,
  "logp_max": 4.0,
  "hbd_max": 6,
  "hba_max": 12,
  "lipinski_violations_max": 2,
  "admet_score_min": 0.6,
  "prv_eligible": true,
  "regulatory_pathway": "PRV_ACCELERATED",
  "constraint_version": "2.0.0",
  "constitutional_compliance": {
    "L51_zero_gaps": true,
    "L10_harm_absolute": true,
    "L9_axiomatic_grounding": true,
    "L5_transparency": true,
    "L11_toxicity_hard_limit": true
  },
  "category": "rare_pediatric",
  "molecular_constraints": {
    "mw_min": 150,
    "mw_max": 600.0,
    "logp_min": -2.0,
    "logp_max": 4.0,
    "hbd_max": 6,
    "hba_max": 12,
    "tpsa_max": 140,
    "rotatable_bonds_max": 10,
    "toxicity_max": 0.015
  },
  "target_profile": {
    "pathogen_type": "genetic",
    "mechanism_classes": [
      "gene_therapy_modifier"
    ],
    "tissue_targets": [
      "cns",
      "muscle",
      "liver"
    ]
  },
  "clinical_requirements": {
    "route": [
      "oral",
      "injectable"
    ],
    "patient_population": "Pediatric patients, weight-based dosing",
    "treatment_setting": "hospital"
  },
  "regulatory": {
    "fda_pathway": "PRV",
    "guidance_document": null,
    "orphan_eligible": true
  }
}
